MTOR and Familial prostate cancer: For maintenance therapy after KT, the use of TAC might be the protective factor of prostate cancer [0.92(0.96~1.00)], while CSA and mTOR could increase the risk of prostate cancer [1.24(1.18~1.31)], [1.31(1.24~1.39)].